These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37227388)

  • 1. Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk.
    Khan MS; Segar MW; Usman MS; Patel KV; Van Spall HGC; DeVore AD; Vaduganathan M; Lam CSP; Zannad F; Verma S; Butler J; Tang WHW; Pandey A
    JACC Heart Fail; 2023 Jul; 11(7):825-835. PubMed ID: 37227388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the WATCH-DM and TRS-HF
    Segar MW; Patel KV; Hellkamp AS; Vaduganathan M; Lokhnygina Y; Green JB; Wan SH; Kolkailah AA; Holman RR; Peterson ED; Kannan V; Willett DL; McGuire DK; Pandey A
    J Am Heart Assoc; 2022 Jun; 11(11):e024094. PubMed ID: 35656988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
    Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; de Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B
    Circulation; 2018 Jul; 138(5):458-468. PubMed ID: 29526832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HF
    Elharram M; Ferreira JP; Huynh T; Ni J; Giannetti N; Verma S; Zannad F; Sharma A
    Diabetes Obes Metab; 2021 Mar; 23(3):782-790. PubMed ID: 33269511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
    Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score.
    Segar MW; Vaduganathan M; Patel KV; McGuire DK; Butler J; Fonarow GC; Basit M; Kannan V; Grodin JL; Everett B; Willett D; Berry J; Pandey A
    Diabetes Care; 2019 Dec; 42(12):2298-2306. PubMed ID: 31519694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial.
    Jain SS; Yu J; Arnott C; Neal B; Perkovic V; Neuen BL; Jardine M; Mahaffey KW
    Int J Cardiol; 2024 Jan; 395():131444. PubMed ID: 37844669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
    Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
    J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
    Sharma A; Wu J; Ezekowitz JA; Felker GM; Udell JA; Heidenreich PA; Fonarow GC; Mahaffey KW; Hernandez AF; DeVore AD
    ESC Heart Fail; 2020 Feb; 7(1):274-278. PubMed ID: 31747132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
    Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW
    J Am Coll Cardiol; 2022 Nov; 80(18):1721-1731. PubMed ID: 36302584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
    Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
    Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC
    Am J Kidney Dis; 2021 Jan; 77(1):23-34.e1. PubMed ID: 32971190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
    Verma S; Sharma A; Zinman B; Ofstad AP; Fitchett D; Brueckmann M; Wanner C; Zwiener I; George JT; Inzucchi SE; Butler J; Mazer CD
    Diabetes Obes Metab; 2020 Jul; 22(7):1141-1150. PubMed ID: 32227432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.
    Sen T; Li J; Neuen BL; Arnott C; Neal B; Perkovic V; Mahaffey KW; Shaw W; Canovatchel W; Hansen MK; Heerspink HJL
    J Am Heart Assoc; 2021 Dec; 10(23):e021661. PubMed ID: 34854308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.
    Lam D; Nadkarni GN; Mosoyan G; Neal B; Mahaffey KW; Rosenthal N; Hansen MK; Heerspink HJL; Fleming F; Coca SG
    Am J Nephrol; 2022; 53(1):21-31. PubMed ID: 35016188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
    Sen T; Li J; Neuen BL; Neal B; Arnott C; Parikh CR; Coca SG; Perkovic V; Mahaffey KW; Yavin Y; Rosenthal N; Hansen MK; Heerspink HJL
    Diabetologia; 2021 Oct; 64(10):2147-2158. PubMed ID: 34415356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial.
    Vaduganathan M; Cannon CP; Jardine MJ; Heerspink HJL; Arnott C; Neuen BL; Sarraju A; Gogate J; Seufert J; Neal B; Perkovic V; Mahaffey KW; Kosiborod MN
    Eur J Heart Fail; 2024 Jun; ():. PubMed ID: 38932575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.